# ğŸ§¾ Exit & Long-Term Value Framework

Owner: Aubert

*Version 1.1 â€“ Strategic Optionality Without Mission Drift*

---

### 1. ğŸ¯ Purpose

This framework governs **Nzilaâ€™s approach to long-term value creation, exit readiness, and stakeholder alignment.**

We do not build to flip. We build to last â€” with the *option* of a transition that multiplies impact, preserves integrity, and honors our contributors.

---

### 2. ğŸ’¡ Nzilaâ€™s Value Thesis

Nzila creates value **by designing systems that outlast hype cycles and extractive models.**

| Value Type | Description |
| --- | --- |
| ğŸ§  **Cultural** | Normalize ethical AI in underserved care communities |
| ğŸ§ª **Clinical** | Deliver measurable gains in cognition, engagement, adherence |
| ğŸ’µ **Commercial** | Drive revenue from real-world use, not vanity metrics |
| ğŸŒ **Ecosystem** | Power third-party tools via APIs, SDKs, and shared Companion UX |
| ğŸ“ˆ **Investor** | Scale without compromising cap table discipline or ethical standards |

> Long-Term Value = (Trust Ã— Scalability Ã— Outcomes)
> 

---

### 3. ğŸ“Š Multi-Horizon Value Creation Plan

| Horizon | Focus | Strategic Outcome |
| --- | --- | --- |
| **H1 â€“ 2025â€“26** | Launch Memora + ClinicConnect | Validate retention, clinical trust |
| **H2 â€“ 2026** | Expand Companion & AI personalization | Ecosystem stickiness, LTV depth |
| **H3 â€“ 2027** | U.S. pilots + CareAI / FamilySync | Market expansion + vertical resilience |
| **H4 â€“ 2028+** | SDK/API commercialization | Platform leverage, licensing readiness |

ğŸ” KPIs we track to assess LTV trajectory:

- Cross-product NPS from clinics and caregivers
- Retention of Companion across products
- Number of opt-in clinics contributing data
- Clinic recommendation/referral rate
- Research publication or co-authorships enabled

---

### 4. ğŸ›¡ï¸ Exit Readiness Philosophy

Nzila does not pursue an exit unless it:

- **Accelerates impact** beyond our current pace
- **Preserves caregiver and clinical trust**
- **Maintains platform integrity and privacy protections**
- **Compensates contributors** fairly and ethically
- **Enables legacy continuation**, not hollow acquisition

> Exit optionality â‰  exit dependency.
> 

---

### 5. âœ… Acceptable Exit Scenarios

| Type | Description | Strategic Fit |
| --- | --- | --- |
| ğŸ”¹ **Strategic Acquisition** | Healthtech or AI firm aligned with Companion vision | âœ… High |
| ğŸ”¹ **Licensing / IP Buyout** | Partial rights sale or co-branded expansion | âœ… Mediumâ€“High |
| ğŸ”¹ **Joint Venture / Regional Spinout** | Country-specific partners (e.g., France, U.S.) | âœ… Medium |
| ğŸ”¹ **NGO Handoff or B-Corp Transition** | Mission-first, foundation-backed continuation | âœ… Lowâ€“Medium |
| ğŸ”¹ **IPO (Long Horizon)** | Only if ARR, ecosystem depth, and impact justify it | âœ… Selective |

---

### 6. ğŸ”’ Non-Negotiables in Any Exit

Nzila will **contractually require**:

- ğŸ” Companion audit rights post-sale
- ğŸ§¾ GDPR, Law 25, and data protection continuation
- ğŸª¢ 12â€“18 months of governance continuity (founder or designee)
- ğŸ’¬ Caregiver/clinic communication plans approved in advance
- ğŸ‡¨ğŸ‡¦ Canadian data storage (or legally equivalent jurisdiction)
- ğŸ§­ Ethical AI Charter adoption by acquirer

---

### 7. ğŸ“ˆ Exit Triggers to Monitor

| Trigger | Type | Review Cadence |
| --- | --- | --- |
| Inbound acquisition interest | Strategic | Quarterly |
| IP licensing inquiries | Commercial | Ad hoc |
| Partner growth beyond platform limits | Operational | Bi-annually |
| Companion reuse potential in new verticals | Technical | Annually |
| Investor appetite for partial liquidity | Financial | Post-round or annually |

---

### 8. ğŸ”§ Internal Readiness Tools

| Tool | Purpose |
| --- | --- |
| ğŸ“ **Shareholder Agreement** | Ensures founder equity, investor fairness |
| ğŸ“„ **IP Assignments** | Secures full product & AI ownership |
| ğŸ” **Data Stewardship Framework** | Exit-proof privacy & security standards |
| ğŸ“‘ **Mission Continuity Clause** | Requires ethical safeguards in any transaction |
| ğŸ§‘â€âš–ï¸ **Exit Oversight Committee** | CEO, legal counsel, and 1 external mission steward |

---

### 9. ğŸ“¢ Exit Communications Strategy

In the event of active exit discussions:

| Stakeholder | Strategy |
| --- | --- |
| **Internal Team** | Asynchronous brief + 1-on-1s with core team |
| **Clinics / Pilots** | Co-branded FAQ, product continuation plan |
| **Caregivers / Users** | In-app + email message, opt-out options clarified |
| **Investors** | Structured slide deck and dilution forecast |